Descrizione riassuntiva della sperimentazione (Fonte di dati: BASEC)
Rückenmarksverletzungen führen meist zu Blasenfunktionsstörungen, welche sich häufig verschlechtern und mit einer Gefährdung der Nierenfunktion und Einschränkung der Lebensqualität einhergehen. Bei dieser schweiz-weiten Studie untersuchen wir die Wirkung der frühzeitigen TTNS auf Blasenfunktionsstörungen nach akuter Rückenmarksverletzung. Insgesamt werden 114 Patienten an den vier Schweizer Spezialkliniken für Rückenmarksverletzte, d.h. in Basel, Nottwil, Sion und Zürich, in die Studie eingeschlossen und nach dem Zufallsprinzip in 2 Gruppen eingeteilt: Bei 57 PatientInnen wird tatsächlich eine Therapie mit TTNS (VERUM) durchgeführt, bei 57 PatientInnen erfolgt nur scheinbar eine Therapie (Scheinbehandlung; SHAM (Placebo). Weder PatientInnen noch behandelnde ÄrztInnen kennen die Gruppen-Zuteilung, es handelt sich um eine doppel-blinde Studie. Die Therapie wird fünfmal wöchentlich für 30 Minuten während 6-9 Wochen durchgeführt. Die Dauer der Studie pro StudienteilnehmerIn beläuft sich auf 1 Jahr, wobei zu 4 festgelegten Zeitpunkten Vor- und Nachuntersuchungen stattfinden. Die Gesamtdauer der Studie beträgt 4 Jahre.
Malattie studiate(Fonte di dati: BASEC)
Patienten, welche kürzlich (bis 40 Tage nach Verletzung) eine Rückenmarksverletzung auf Höhe der Hals- oder Brustwirbel erlitten haben.
Health conditions
(Fonte di dati: WHO)
Spinal Cord Injury, Acute
Malattia rara
(Fonte di dati: BASEC)
No
Interventi esaminati (p. es. medicamento, terapia, campagna)
(Fonte di dati: BASEC)
In dieser Studie wird die Wirkung der frühzeitigen elektrischen Stimulation des Schienbein-Nervs (transkutane tibiale Nervenstimulation (TTNS)) auf Blasenfunktionsstörungen nach akuter Rückenmarks-verletzung untersucht. Bei 57 PatientInnen wird tatsächlich eine Therapie mit TTNS (VERUM) durchgeführt, bei 57 PatientInnen erfolgt nur scheinbar eine Therapie (Scheinbehandlung; SHAM (Placebo). Die Therapie wird fünfmal wöchentlich für 30 Minuten während 6-9 Wochen durchgeführt.
Interventions
(Fonte di dati: WHO)
Device: VERUM TTNS;Device: SHAM TTNS
Criteri per la partecipazione alla sperimentazione
(Fonte di dati: BASEC)
- > 18 Jahre
- Patienten mit akuter Rückenmarksverletzung auf Höhe der Hals- oder
Brustwirbel (bis 40 Tage nach Verletzung)
- Schriftliche Einverständniserklärung
Criteri di esclusione
(Fonte di dati: BASEC)
- < 18 Jahre
- Personen mit Kontraindikationen für die Anwendung der elektrischen
Stimulation
- Aktuelle Behandlung mit Antimuskarinika oder Mirabegron
Inclusion/Exclusion Criteria
(Fonte di dati: WHO)
Gender: All
Maximum age: N/A
Minimum age: 18 Years
Inclusion Criteria:
- Age >18 years
- Patients with acute SCI (traumatic SCI and sudden onset (<7 days) non-traumatic SCI)
within 40 days after injury
- Patients with acute SCI at cervical or thoracic level
- Willing to take part and follow the requirements of the TASCI protocol (up to one year
after SCI)
- no percutaneous tibial nerve stimulation (PTNS)
- no functional electrical stimulation (FES), apart from upper limb FES
- no electrical muscle stimulation (EMS)
- Informed Consent
Exclusion Criteria:
- Contraindications to the investigational product
- DO with contractions greater than 40 cmH2O at a bladder filling volume of less than
500mL at baseline visit
- Treatment with antimuscarinics or with mirabegron
- Known or suspected non-adherence, drug or alcohol abuse
- Inability to follow the procedures of the study, e.g. due to language problems,
psychological disorders, dementia, etc. of the participant
- Participation in another study with investigational drug or product within the 30 days
preceding and during the present study
- Neuromodulation treatment for urological or bowel indication in the last six months or
ongoing
- Botulinum toxin injections in the detrusor and/or urethral sphincter in the last six
months
- Bilaterally absent tibial nerve compound muscle action potential (cMAP, amplitude <
1mV)
- Women who are pregnant or breast feeding
- Intention to become pregnant during the course of the study
- Individuals especially in need of protection (according to Research with Human
Subjects published by the Swiss Academy of Medical Sciences
[www.samw.ch/en/News/News.html])
- Enrolment of the investigator, his/her family members, employees and other dependent
persons
- Pre-existing or concomitant medical condition apart from SCI that might pose a safety
issue or would interfere with interpretation of study results or study conduct (e.g.
Parkinson's disease, neurodegenerative disorders including multiple sclerosis and
amyotrophic lateral sclerosis, urological malignancies)
-
Altre informazioni sulla sperimentazione
Stato di reclutamento
Recruiting
Titolo scientifico
(Fonte di dati: WHO)
Transcutaneous Tibial Nerve Stimulation in Patients With Acute Spinal Cord Injury to Prevent Neurogenic Detrusor Overactivity: A Nationwide Randomised, Sham-controlled, Double-blind Clinical Trial
Tipo di sperimentazione
(Fonte di dati: WHO)
Interventional
Disegno della sperimentazione
(Fonte di dati: WHO)
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Triple (Participant, Care Provider, Outcomes Assessor).
Fase
(Fonte di dati: WHO)
N/A
Punti finali primari
(Fonte di dati: WHO)
The occurrence of neurogenic DO jeopardizing the upper urinary tract
Punti finali secondari
(Fonte di dati: WHO)
Volumetric changes during urodynamics and their relation to clinical outcomes;Changes in bladder compliance [mL/cmH2O] during urodynamics and their relation to clinical outcomes;Pressure changes during urodynamics and their relation to clinical outcomes;Changes in maximum flow rate [mL/s] as assessed by urodynamics and their relation to clinical outcomes;Changes in vesicoureterorenal reflux (VUR) as assessed by videography during urodynamics and their relation to clinical outcomes;Changes in pelvic floor activity as assessed by electromyography (EMG) during urodynamics and their relation to clinical outcomes;Changes in bladder storage and voiding parameters and their relation to clinical outcomes;Changes in bowel diary parameters and their relation to clinical outcomes;Changes in International Prostate Symptom (IPSS) questionnaire and their relation to clinical outcomes;Changes in urinary symptoms as assessed by the Urinary Symptom Profile (USP) questionnaire and their relation to clinical outcomes;Changes in Qualiveen questionnaire scores and their relation to clinical outcomes;Changes in Female Sexual Function Index (FSFI) and their relation to clinical outcomes;Changes in International Index of Erectile Function (IIEF) and their relation to clinical outcomes;Changes in International Spinal Cord Society (ISCoS) Female / Male sexual function data sets and their relation to clinical outcomes;Changes in Neurogenic Bowel Dysfunction (NBD) score and their relation to clinical outcomes;Volumetric changes during rectal sensitivity testing and barostat assessment and their relation to clinical outcomes;Pressure changes during anorectal manometry and barostat assessment and their relation to clinical outcomes;Changes in rectal compliance [mL/cmH2O] during anorectal manometry and barostat assessment and their relation to clinical outcomes;Changes in defecatory disorder [Rao's classification] identified during anorectal manometry and their relation to clinical outcomes;Changes International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) protocol;Changes in Lower Extremities Motor Scale (LEMS) from International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) protocol;Changes in Upper Extremities Motor Scale (UEMS) from International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) protocol;Changes in Spinal Cord Independence Measure III (SCIM-III) and their relation to clinical outcomes;Changes in spasticity in the knee and elbow flexors and extensors from the Modified Ashworth Scale (MAS) assessment and their relation to clinical outcomes;Changes in spasticity in daily life as assessed by the Spinal Cord Injury Spasticity Evaluation Tool (SCI-SET) questionnaire and their relation to clinical outcomes;Changes in neurophysiology measurements of evoked potentials (EPs) as well as nerve conduction measurements and their relation to clinical outcomes;Changes in lower urinary tract (LUT) neurophysiology: Current perception thresholds (CPTs) and LUT sensory evoked potentials (LUTSEPs) with their relation to clinical outcomes;Changes in frequency power of surface electromyography (EMG) and electroencephalography (EEG) and their relation to clinical outcomes;Changes in EMG and EEG coherence measures and their relation to clinical outcomes;Changes in white and gray matter area in the lumbosacral enlargement (LSE) and their relation to clinical outcomes;Changes in white and gray matter area in upper cervical cord (at C2/C3) and their relation to clinical outcomes;Changes in white and gray matter volume of the conus medullaris (CM) and their relation to clinical outcomes;Changes in gray and white matter volume in the brain and their relation to clinical outcomes;Changes in fractional anisotropy (FA) in the brain and spinal cord and their relation to clinical outcomes;Changes in diffusivity in the brain and spinal cord and their relation to clinical outcomes;Changes in brain and spinal cord tissue microstructure and their relation to clinical outcomes;Expression profile of microRNA (miRNA) in urine and blood as well as their relation to clinical outcomes;Changes in inflammatory markers in bladder tissue, blood, and urine, as well as their relation to clinical outcomes;Changes in levels of neurotransmitters (neurotrophins) in blood, and urine, as well as their relation to clinical outcomes;Changes in the composition of urinary and stool microbiome and their relation to clinical outcomes;Changes in bladder tissue and their relation to clinical outcomes
Contatto per informazioni
(Fonte di dati: WHO)
Please refer to primary and secondary sponsors
Risultati della sperimentazione
(Fonte di dati: WHO)
Sintesi dei risultati
ancora nessuna informazione disponibile
Collegamento ai risultati nel registro primario
ancora nessuna informazione disponibile
Informazioni sulla disponibilità dei dati dei singoli partecipanti
ancora nessuna informazione disponibile
Siti di esecuzione della sperimentazione
Siti di esecuzione in Svizzera
(Fonte di dati: BASEC)
Basilea, Nottwil, Sion, Zurigo
Paesi di esecuzione
(Fonte di dati: WHO)
Switzerland
Contatto per maggiori informazioni sulla sperimentazione
Dati della persona di contatto in Svizzera
(Fonte di dati: BASEC)
Dr. Martina Liechti
+41 44 510 72 05
martina.liechti@balgrist.ch
Contatto per informazioni generali
(Fonte di dati: WHO)
Thomas M. Kessler, Prof. Dr. med.;Armin Curt, Prof. Dr. med.;Martin Brinkhof, Dr.;J?rgen Pannek, Prof. Dr. med.
University of Zurich;Balgrist University Hospital;Swiss Paraplegic Research, Nottwil;Swiss Paraplegic Centre
+41 44 386 39 07
thomas.kessler@balgrist.ch
Contatto per informazioni scientifiche
(Fonte di dati: WHO)
Thomas M. Kessler, Prof. Dr. med.;Armin Curt, Prof. Dr. med.;Martin Brinkhof, Dr.;J?rgen Pannek, Prof. Dr. med.
University of Zurich;Balgrist University Hospital;Swiss Paraplegic Research, Nottwil;Swiss Paraplegic Centre
+41 44 386 39 07
thomas.kessler@balgrist.ch
Autorizzazione da parte della commissione d’etica (Fonte di dati: BASEC)
Nome della commissione d’etica che rilascia l’autorizzazione (nel caso di studi multicentrici solo la commissione direttiva)
Kantonale
Ethikkommission Zürich
Data di autorizzazione da parte della commissione d’etica
29.01.2020
Altri numeri di identificazione delle sperimentazioni
Numero di identificazione della sperimentazione della commissione d’etica (BASEC-ID)
(Fonte di dati: BASEC)
2019-00074
Torna alla panoramica
